New York, NY (PRWEB) August 09, 2012
The Lymphoma Research Foundation (LRF) has announced the election of six experts in the field of lymphoma research to its Scientific Advisory Board (SAB):
Steven H. Bernstein, M.D. is Professor of Medicine and Co-Director of the Lymphoma Biology Program at the James P. Wilmot Cancer Center, University of Rochester Medical Center in New York, NY. He serves as a member of the Lymphoma Working Group, Lymphoma Core Committee, and Lymphoma Biology Committee of the Southwest Oncology Group (SWOG). Dr. Bernstein has been awarded numerous grants to study hematologic malignancies and has been the principal investigator for many clinical protocols in lymphomas and leukemias. Dr. Bernstein earned his medical degree from the New York University School of Medicine. Subsequently, he was a clinical fellow in hematology and oncology at Beth Israel Hospital in Boston, MA and a research fellow in medicine in the Laboratory of Clinical Pharmacology at Dana-Farber Cancer Institute.
Kristie A. Blum, M.D. is the Co-Director of the Lymphoma Program and Associate Professor of Medicine in the Division of Hematology at The Ohio State University School of Medicine. Dr. Blum is an expert in the clinical development of novel therapies for patients with aggressive B-cell non-Hodgkin (NHL) and Hodgkin lymphoma (HL). She has served as the principal investigator on several phase I and II trials in patients with B-cell chronic lymphocytic leukemia and NHL and has developed several investigator-initiated trials. Since 2006, she has served as a member of the Lymphoma Committee for the Cancer and Leukemia Group B (CALGB), now known as the Alliance, which is a national clinical research group sponsored by the National Cancer Institute. Dr. Blum earned her Medical Degree from the University of Miami School of Medicine and completed fellowships in Hematology/Oncology at both Vanderbilt University in Nashville, TN and at Washington University in St. Louis, MO.
Kieron Dunleavy, M.D. is an attending physician and investigator in the metabolism branch of the National Cancer Institute. Dr. Dunleavy’s research interests focus on the biology and treatment of lymphoproliferative disorders, particularly diffuse large B-cell lymphoma and Burkitt lymphoma. He is interested in developing novel targeted therapies for lymphoma and developing novel strategies that reduce toxicity in aggressive lymphomas such as Burkitt and primary mediastinal B-cell lymphomas. Dr. Dunleavy is a member of several national organizations, including the American Society of Hematology (ASH) and the American Society of Oncology. Dr. Dunleavy earned his medical degree from University College Dublin, Ireland. Following residency and fellowship training in Dublin, he completed a fellowship in medical oncology at the National Cancer Institute.
Nathan H. Fowler, M.D. is an Assistant Professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center in Houston, TX. Dr. Fowler serves as chairman of several phase 1 and investigator-initiated phase II trials for patients with non-Hodgkin lymphoma. His works include conducting the largest study to use immunomodulatory drugs in combination for untreated low-grade lymphoma and leading the first phase I trial demonstrating activity of a Bruton’s tyrosine kinase (BTK) inhibitor in humans. Dr. Fowler’s primary clinical research interest is to further develop novel therapeutic regimens utilizing biologic and immunomodulatory agents to benefit patients with low-grade non-Hodgkin lymphoma. Dr. Fowler earned his medical degree from the University of Texas Medical Branch, where he remained for his internship and residency. He completed his clinical fellowship at Georgetown University in Washington, DC.
Stephanie A. Gregory, M.D., FACP is the Elodia Kehm Chair of Hematology and Professor of Medicine at Rush University Medical Center, Rush University in Chicago, IL. Dr. Gregory’s research interests include Hodgkin and non-Hodgkin lymphomas, leukemias and myelomas, especially using novel approaches of immunotherapy. She has been involved in several radioimmunotherapy trials over the years for non-Hodgkin lymphoma and is presently involved in clinical trials with small molecules targeted to malignant lymphoma - cells. Dr. Gregory is an active memberof the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO). Dr. Gregory earned her medical degree with honors from the Woman’s Medical College of Pennsylvania in Philadelphia, PA. Her postgraduate training included an internship, residency, chief residency and hematology fellowship at Rush University Medical Center.
Ann S. LaCasce, M.D. is an Assistant Professor of Medicine at Harvard Medical School and attending physician at Dana-Farber Cancer Institute. She also serves as the Director of Hematology/Oncology Fellowships for the Brigham and Women’s Medical Residency Program. Dr. LaCasce’s research includes developing therapeutic trials in aggressive non-Hodgkin and Hodgkin lymphomas using rational therapies. She is the principal investigator for using positron emission tomography (PET) to risk stratify therapy in patients with bulky Hodgkin lymphoma. Dr. LaCasce serves as a member of the National Comprehensive Cancer Institute’s Lymphoma Executive Committee, which develops guidelines for the treatment of non-Hodgkin lymphoma. Dr. LaCasce earned her medical degree from Tufts University School of Medicine and her Master of Medical Sciences from Harvard University Medical School. She completed the Dana-Farber/Partners Cancer Care Hematology/Oncology fellowship program in Boston, MA.
“We look forward to the contributions of these talented physicians and researchers as members of our world-renowned Scientific Advisory Board,” said LRF Chief Executive Officer Diane Blum.
Comprised of the world’s leading lymphoma researchers and oncologists, the Scientific Advisory Board formulates the LRF research portfolio, seeking out the most innovative and promising lymphoma research projects for support. The 45-member SAB reviews grant proposals and makes recommendations regarding research priorities and funding to the Foundation Board of Directors. The SAB also evaluates the progress of on-going research projects and guides the strategic direction of the Foundation’s research programs and consortia.
The new members’ five-year terms began July 1, 2012.
“The Lymphoma Research Foundation and the lymphoma community will benefit immensely from the insight and expertise of the Scientific Advisory Board’s newly elected members,” said SAB Chair John P. Leonard, M.D. “I look forward to working with all of the members of the Scientific Advisory Board to advance LRF’s mission of eradicating lymphoma.”
About the Lymphoma Research Foundation
The Lymphoma Research Foundation (LRF) is the nation's largest non-profit lymphoma organization devoted to funding innovative research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives and patient services. To date, LRF has awarded more than $51 million in lymphoma-specific research. For additional information on LRF’s programs and services, visit lymphoma.org.